Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy
NCT00179608
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
28
Enrollment
INDUSTRY
Sponsor class
Conditions
Malignant Melanoma
Interventions
DRUG:
CC-5013
Sponsor
Celgene
Collaborators
[object Object]